.@publiceye_ch lehnt die #KVV Vorlage zu Medikamentenpreisen in🇨🇭ab. Die Einsparungen bleiben gering, solange nichts gegen die Machtasymmetrie zwischen #Pharma & @BAG_OFSP_UFSP unternommen wird. Es braucht eine gründlichere Reform und mehr Transparenz! publiceye.ch/de/news/detail/…
1
29
Unsere Recherchen zeigen die riesigen Profitmargen der #Pharma in der 🇨🇭. Es besteht insbesondere bei hochpreisigen Medikamenten enormes Sparpotenzial, ohne dass dadurch die Innovation oder die Versorgungssicherheit gefährdet würden. publiceye.ch/de/mediencorner…
50
Public Eye rejette le projet de révision #OAMal sur le prix des médicaments en🇨🇭. Les économies resteront modestes tant qu'on n'agira pas sur l'asymétrie de pouvoir entre #pharma et @BAG_OFSP_UFSP. Il faut une réforme plus drastique & plus de transparence! publiceye.ch/fr/news/detail/…
1
30
Nos enquêtes ont révélé des marges bénéficiaires gigantesques réalisées par la #pharma en🇨🇭. Le potentiel d’économie est énorme sur les médicaments très chers – sans pour autant mettre en péril l’innovation, l’approvisionnement ou leur viabilité financière publiceye.ch/fr/coin-medias/…
55
Patrick Durisch (@dbdurisch.bsky.social) retweeted
A new book by @realtahiramin and Rohit Malpani is now available in the U.S.
Pharma Monopoly: The Battle for the Future of Medicines examines the origins of outdated patent rules and economic policies that champion monopolies over the public interest.
🔗wiley.com/en-us/Pharma+Monop…
Patrick Durisch (@dbdurisch.bsky.social) retweeted
In this excerpt from Chapter 5 of Pharma Monopoly, titled “The Innovation Trap,” we explain how the pharmaceutical industry has weaponized the word “innovation” to ensure a perpetual novelty of knowledge that should be in the public domain.
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.” trib.al/DCQtAfp
Patrick Durisch (@dbdurisch.bsky.social) retweeted
The WHO is deciding this now. EU & Norway are to blame but they can change course.
We need a fair & equitable pathogen access and benefit-sharing system 🌍 #fairpabs
Sign fairpabs.org
A virus or bacteria's digital sequence information uploaded by a public lab in Recife or Nairobi re-emerges as intellectual property owned in the US or Europe.
No trace. No obligation. No return.
This injustice cannot go on. Sign the petition fairpabs.org #fairpabs
33
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Excellent @ICIJorg longform piece on #pharma drug pricing - specifically focused #Merck's secretive pricing of its blockbuster drug Keytruda.
icij.org/investigations/canc…
Worth flagging this part of it:
Thank you @realtahiramin @IMAKglobal for supporting
@PublicEyeSuisse in our patent analysis of cancer drug #Keytruda, in conjunction with @ICIJorg, unveiling Merck/MSD's gaming of the patent systems to maintain overinflated prices & delay competition publiceye.ch/en/topics/pharm…
Replying to @realtahiramin
What @ICIJorg found aligns with what we, and others, have found: Merck has built a multi-pronged patent abuse scheme to fortify its Keytruda monopoly and maintain high prices.
In this story, @publiceye_ch also shared with @ICIJorg an exclusive estimate of Merck/MSD's R&D costs for #pembrolizumab based on independent verifiable data. These represent just a tiny fraction of what MSD pretends ➡️$1.9bn vs >$30bn.
Check it out here👉publiceye.ch/en/topics/pharm…
2
44
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Publicamos la Investigación global "The Cancer Calculus" (icij.org/investigations/canc…), coordinada por @ICIJorg, con participación del equipo argentino: @iruiz, @halconada, @marielfitz, @spcrucianelli, @Emiliadelfino, @edlitvin y @rgbrom
elruido.org/argentina-un-cas…
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Este medicamento puede salvar vidas, pero se vende hasta dos veces más caro en #Guatemala que en Europa.
Mientras la farmacéutica Merck gana millones, pacientes con cáncer deben pelear contra el sistema para acceder a Keytruda, #LaMedicinaDelMillón. 💊 lnk.bio/s/a2daf
Patrick Durisch (@dbdurisch.bsky.social) retweeted
💸¿Por qué un fármaco contra el cáncer de #Merck es inaccesible para muchos pacientes?
#Pembrolizumab (Keytruda) cuesta US$65.000 por terapia en Perú si lo cubre el SIS, y el doble el privado. Una investigación de @ICIJorg, que integra #SaludConLupa, revela el negocio detrás.🧵
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Full set of Principles for Access to Medicines and Trade: citizen.org/news/more-than-1…
Patrick Durisch (@dbdurisch.bsky.social) retweeted
The Trump administration is using U.S. trade power and extreme tariffs to bully other countries into binding agreements that undermine affordable and readily available access to medicines.
Experts from around the world offer an alternate vision:

ALT Teal background with highlighted quote: "Pro-corporate, pro monopoly models reinforced by the current trade order and exploited by the powerful are failing the world. Health must be a guarantee, not a bargaining chip." Blue background with caption: "Over 100 organizations around the world detail principles for trade that ensure access to medicines."
Plutôt une vaste farce qu'un accord, un peu comme les soldes : des % en apparence élevés mais sur des prix catalogue fictifs, avec un impact mineur pour les patient·e·s 🇺🇸 mais majeur pour #BigPharma. Qui exigera en retour une hausse indécente en🇨🇭🇪🇺... rts.ch/info/economie/2025/ar…
1
36
Belgian Regulator Presses Roche Further Over Biosimilar Abuse Allegations insights.citeline.com/pink-s…
1
1
28
.@PublicEyeSuisse extensively reported about Roche's patent evergreening strategy on its breast cancer treatments trastuzumab & follow-on products. This led to complaints by competition authorities a.o. in South Africa. When will 🇨🇭start to act? publiceye.ch/en/topics/pharm…















